MCM
PGNX

Moore Capital Management’s Progenics Pharmaceuticals Inc PGNX Stock Holding History

Moore Capital Management’s Portfolio PGNX Stock Details PGNX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q4 		– Sell
-125,000
Closed -$632K – 402
2019
Q3 		$632K Buy
125,000
+25,000
+25% +$125K 0.03% 247
2019
Q2 		$617K Hold
100,000
– – 0.01% 263
2019
Q1 		$464K Hold
100,000
– – 0.01% 257
2018
Q4 		$420K Hold
100,000
– – 0.02% 197
2018
Q3 		$627K Buy
+100,000
New +$768K 0.01% 243
2014
Q1 		– Sell
-95,000
Closed -$506K – 553
2013
Q4 		$506K Buy
95,000
+45,000
+90% +$198K 0.01% 348
2013
Q3 		$252K Buy
+50,000
New +$271K 0.01% 340

Other funds holding PGNX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
FCM
Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
EAM
Eagle Asset Management St Petersburg, Florida $19.6B AUM 41.58% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
CTA
Carillon Tower Advisers St. Petersburg, Florida $16.4B AUM 64.75% 1-Year Est. Return
BC
Broadfin Capital New York $747M AUM 100.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Moore Capital Management's PGNX Position: Q4 2019 in Review

Moore Capital Management sold out of Progenics Pharmaceuticals Inc (PGNX) in Q4 2019, closing a stake of 125,000 shares — an estimated $632K sold.

Moore Capital Management first reported a position in PGNX in Q3 2013 and held it in 7 quarters. The position peaked at $632K in Q3 2019. 128 funds tracked by Wall St. Rank hold PGNX as of Q4 2019.

  • Moore Capital Management reported no remaining Progenics Pharmaceuticals Inc position as of Q4 2019 after selling out during the quarter.
  • Moore Capital Management sold 125,000 Progenics Pharmaceuticals Inc shares in Q4 2019, an estimated $632K.
  • Moore Capital Management first reported a position in Progenics Pharmaceuticals Inc in Q3 2013 and held it in 7 quarters.
  • Moore Capital Management's Progenics Pharmaceuticals Inc position peaked at $632K in Q3 2019.
  • 128 funds tracked by Wall St. Rank held Progenics Pharmaceuticals Inc as of Q4 2019.

Based on Moore Capital Management's 13F filing for Q4 2019, filed 14 Feb 2020.